Alzheimer's Disease (AD)
Conditions
Keywords
mild cognitive impairment, dementia, biomarkers
Brief summary
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.
Interventions
None listed
Sponsors
Parkwood Hospital, London, Ontario
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Individual with MCI (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA) 2. MoCA score must be 18 to 28 inclusive 3. Age 55 to 80 years inclusive 4. Has a study partner that is willing to participate as a source of information and has approximately weekly contact with the subject (contact can be in-person, via telephone or electronic communication). The study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the subject's daily function. 5. Group A - must have a clinical memory assessment appointment scheduled at Parkwood Institute within 18 months of baseline 6. Group B - must have had a clinical memory assessment appointment at Parkwood Institute within 18 months of baseline
Exclusion criteria
* 1\) Participants who fulfill diagnostic criteria for MCI or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (eg, MCI/dementia due to frontotemporal lobar degeneration, diffuse Lewy body disease, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, etc). 2\) Presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest Huntington's disease, multiple sclerosis, Parkinson's disease, Down's syndrome, active alcohol/drug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder. 3\) Current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures 4) History of epilepsy, fits, or unexplained blackouts other than vasovagal syncope within 10 years before screening. 5\) Malignant neoplasms within 3 years (except for basal cell or squamous cell carcinoma in situ of the skin) 6) Women of child bearing potential and breastfeeding mothers 7) Individuals who require sedation to complete PET scan. 8) Individuals who are unable to complete assessments in the English language. 9) Individuals who cannot provide consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the feasibility of integrating a CSF biomarker into diagnostic decision making for AD. | through study completion, approximately 1 year | Analysis of resources needed to conduct testing including personnel required, time requirements, space, and resources/equipment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the impact of biomarker results on participants | through study completion, approximately one year | Determined by Participant Pre and Post Biomarker Questionnaire |
| Evaluate the clinical utility of CSF and PET biomarkers in the diagnostic algorithm. | through study completion, approximately one year | Measured by investigator pre and post biomarker questionnaire indicating clinical suspicion, confidence of clinical suspicion, tests to be ordered, and management plan. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Determine the correlation between the plasma biomarker results and CSF results and amyloid PET results | through study completion, approximately one year | Measured by the percent agreement between plasma biomarker and CSF results and amyloid PET results |
Countries
Canada
Outcome results
None listed